Imanova: investing in know-how

Given the spiralling costs and ever-present risks associated with developing a new drug, pharmaceutical companies are always looking for ways to shorten the pathway from lab bench to clinic.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

Europe

How AI will be shaped by legal and regulatory developments in 2026

9 January 2026 Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.

Europe

Deadline extended: Who are the world’s best in-house counsel?

9 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

More features

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Carpmaels & Ransford builds Munich UPC team with elite hire

Why the US is poised for a patent litigation surge in 2026

How AI will be shaped by legal and regulatory developments in 2026

Deadline extended: Who are the world’s best in-house counsel?

Arnold & Porter loses another regulatory partner to growing rival

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Imanova: investing in know-how

More on this story

Editor's picks

Editor's picks

More features